Health Care [ 7/12 ] | Biotechnology [ 56/74 ]
NASDAQ | Common Stock
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
The company is developing Bempikibart (ADX-914), a fully human anti"interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
It also develops ADX-096, a C3d mAb " CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications.
The company was founded in 2017 and is based in Waltham, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 26 | -0.54 Increased by +40.00% | -0.68 Increased by +20.59% |
| Mar 10, 26 | 4.58 Increased by +494.83% | -0.86 Increased by +632.56% |
| Nov 13, 25 | -0.60 Increased by +58.82% | -1.19 Increased by +49.58% |
| Aug 6, 25 | -0.78 Increased by +45.07% | -0.80 Increased by +2.50% |
| May 7, 25 | -0.90 Increased by +93.98% | -1.23 Increased by +26.83% |
| Mar 11, 25 | -1.16 Decreased by -314.29% | -1.53 Increased by +24.18% |
| Nov 12, 24 | -1.46 Decreased by -155.61% | -1.40 Decreased by -4.07% |
| Aug 8, 24 | -1.42 Decreased by -132.79% | -1.04 Decreased by -36.54% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 0.00 Decreased by N/A% | -7.61 M Increased by +31.02% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 25 | 53.74 M Increased by +N/A% | 57.73 M Increased by +506.86% | Increased by +107.43% Decreased by N/A% |
| Sep 30, 25 | 0.00 Decreased by N/A% | -7.39 M Increased by +58.01% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 25 | 0.00 Decreased by N/A% | -9.49 M Increased by +44.11% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 0.00 Decreased by N/A% | -11.03 M Decreased by -1.17 K% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Increased by +100.00% | -14.19 M Increased by +47.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -17.59 M Decreased by -25.40% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by -100.00% | -16.98 M Decreased by -192.37% | Decreased by N/A% Decreased by N/A% |